The inhibitory effect of esmolol on human plasmacholinesterase

Barabás, Éva; Zsigmond, Elemér K.; Kirkpatrick, Anthony F.

doi:10.1007/bf03010746

Cited by 6 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different drugs may either decrease or increase the activity of BuChE and AChE. Inhibition of plasma BuChE in rats and humans may be caused by organophosphorus herbicides such as glyphosate (8), reversible cholinesterase inhibitors (9), glucocorticoids (10,11), or some beta blockers (12). In humans, low plasma BuChE activity may reduce succinylcholine hydrolysis and prolong respiratory depression (13).…”

mentioning

confidence: 99%

Effects of simvastatin and fenofibrate on butyrylcholinesterase activity in the brain, plasma, and liver of normolipidemic and hyperlipidemic rats

Vukšić

Lovrić

Konjevoda

et al. 2019

Archives of Industrial Hygiene and Toxicology

View full text Add to dashboard Cite

The study objective was to test the hypothesis that simvastatin and fenofibrate should cause an increase in butyrylcholinesterase (BuChE) activity not only in the plasma and liver but also in the brain of normolipidemic and hyperlipidemic rats. Catalytic enzyme activity was measured using acetylthiocholine (ATCh) and butyrylthiocholine (BTCh) as substrates. Normolipidemic and hyperlipidemic rats were divided in four groups receiving 50 mg/kg of simvastatin a day or 30 mg/kg of fenofibrate a day for three weeks and three control groups receiving saline. Simvastatin and fenofibrate caused an increase in brain BuChE activity in both normo- and hyperlipidemic rats regardless of the substrate. The increase with BTCh as substrate was significant and practically the same in normolipidemic and hyperlipidemic rats after simvastatin treatment (14–17% vs controls). Simvastatin and fenofibrate also increased liver and plasma BuChE activity in both normolipidemic and hyperlipidemic rats regardless of the substrate. In most cases the increase was significant. Considering the important role of BuChE in cholinergic transmission as well as its pharmacological function, it is necessary to continue investigations of the effects of lipid-lowering drugs on BuChE activity.

show abstract

mentioning

confidence: 99%

Effects of simvastatin and fenofibrate on butyrylcholinesterase activity in the brain, plasma, and liver of normolipidemic and hyperlipidemic rats

Vukšić

Lovrić

Konjevoda

et al. 2019

Archives of Industrial Hygiene and Toxicology

View full text Add to dashboard Cite

show abstract

Reply (1)

Chung

Silverman

1993

Can J Anaesth

View full text Add to dashboard Cite

EsmololTo the Editor: I read with interest the recent editorial and original paper on the cardioselective beta blocker, esmolol. ~.a Chung's conclusion that esmolol 2 mg. kg -~ is effective in obtunding the haemodynamic response to laryngoscopy and intubation concurs with our findings in another stressful situation, electroconvulsive therapy. 3 As Chung's study involved the use of a rapid-sequence induction technique with high dosages of succinylcholine (1.5 mg. kg-~), it is important to consider the possible theoretical drug interaction. Both esmolol and succinylcholine are metabolized by esterases and their combined administration may be associated with prolonged duration of action.

show abstract

Pharmacology of Muscle Relaxants and Their Antagonists

Naguib¹,

Lien²

2010

Miller's Anesthesia

View full text Add to dashboard Cite

The inhibitory effect of esmolol on human plasmacholinesterase

Cited by 6 publications

References 12 publications

Effects of simvastatin and fenofibrate on butyrylcholinesterase activity in the brain, plasma, and liver of normolipidemic and hyperlipidemic rats

Effects of simvastatin and fenofibrate on butyrylcholinesterase activity in the brain, plasma, and liver of normolipidemic and hyperlipidemic rats

Reply (1)

Pharmacology of Muscle Relaxants and Their Antagonists

Contact Info

Product

Resources

About